Fabry Disease Clinical Trials | Amicus Therapeutics
← Amicus Clinical Trials

Fabry Disease Clinical Trials

Note to healthcare providers and patients: Study 042 and program 188 in the U.S. will close in the second half of 2018. Amicus Therapeutics will provide support to patients and healthcare providers to help provide continued access to treatment. For more information, contact clinicaltrials@amicusrx.com


Migalastat Monotherapy: Phase 3 Long-Term Safety Study 042 (AT1001-042 Study)

More information: www.clinicaltrials.gov: NCT02194985


Migalastat Monotherapy: Physician Initiated Request (MGM116188)

More information: www.clinicaltrials.gov: NCT01476163